Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 726-731    DOI: 10.31083/j.ejgo.2020.05.5219
Original Research Previous articles | Next articles
Criteria for predicting ovarian metastasis in early-stage cervical adenocarcinoma
Qihua Yi1, 2, , Lin Chen1, , Sijing Chen1, Ying Zheng1, 3, *()
1West China Second University Hospital, Chengdu, Sichuan, P. R. China
2Chongqing Three Gorges Central Hospital, Chongqing, P. R. China
3Key Laboratory of Obstetrics and Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, P. R. China
Download:  PDF(359KB)  ( 110 ) Full text   ( 5 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objectives: To evaluate the clinicopathologic risk factors for and construct criteria to predict the risk of ovarian metastasis in early-stage cervical adenocarcinoma. Materials and Methods: Subjects were cervical adenocarcinoma patients with International Federation of Gynecology and Obstetrics (FIGO) Stage less than or equal to IIB who underwent hysterectomy and bilateral salpingo-oophorectomy and pelvic lymphadenectomy at this institution between January 2010 and December 2017. Clinicopathologic variables were studied by univariate and logistic regression analysis to identify the risk factors, and then criteria were built. Results: Four hundred and nineteen patients were enrolled in the study, and ovarian metastasis rate was 4.50% (19/419). Eight patients had normal appearance, and 14 patients had bilateral ovarian metastases. Univariate analysis revealed that clinical stage (p < 0.001), preoperative hemoglobin (p = 0.017), preoperative red blood cell count (p = 0.001), histology type (p < 0.001), deep cervical stromal invasion (p < 0.001), lymphatic vascular space invasion (p < 0.001), parametrial invasion (p < 0.001), marginal invasion (p < 0.001), vaginal invasion (p < 0.001), uterine corpus invasion (p < 0.001), fallopian tube invasion (p < 0.001), and pelvic lymph node metastasis (p < 0.001) were associated with ovarian metastasis. The logistic regression analysis revealed that clinical stage (odds ratio, OR, 11.747; 95% confidence interval, CI, 1.969-70.082), histology type (OR, 5.069; 95% CI, 1.249-24.904), lymphatic vascular space invasion (OR, 13.369; 95% CI, 2.194-81.469,) and fallopian tube invasion (OR, 124.305; 95% CI, 20.969-736.871) were independently associated with ovarian metastasis. When the clinical stage, histology type, lymphatic vascular space invasion, and fallopian tube invasion were considered as high-risk factors for ovarian metastasis, the sensitivity, specificity, positive predictive value, and negative predictive value were found to be 100.00%, 58.76%, 10.00%, 100.00%, and 60.57%, respectively. Conclusion: Clinical stage, histology type, lymphatic vascular space invasion, and fallopian tube metastasis may be used in the prediction of ovarian metastasis in early-stage cervical adenocarcinoma.
Key words:  Adenocarcinoma      Ovarian metastasis      Ovarian preservation      Clinical risk factors     
Submitted:  05 February 2020      Accepted:  01 April 2020      Published:  15 October 2020     
*Corresponding Author(s):  YING ZHENG     E-mail:  zhy_chd@126.com
About author:  Contributed equally.

Cite this article: 

Qihua Yi, Lin Chen, Sijing Chen, Ying Zheng. Criteria for predicting ovarian metastasis in early-stage cervical adenocarcinoma. European Journal of Gynaecological Oncology, 2020, 41(5): 726-731.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.5219     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/726

[1] Youngsun Kim, Sungkyoung Moon, Kiyong Na. Metastatic mesonephric adenocarcinoma of unknown origin after hysterectomy: A case report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 828-832.
[2] Špela Smrkolj, Snježana Frković Grazio, Renata Košir Pogačnik. Endocervical adenocarcinoma in situ with ovarian metastasis: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 802-805.
[3] U. Indraccolo, R. Martinello, G. Scutiero, G. Bernardi, C. Borghi, O. Brasile, P. Greco. Ten-year survival in patients with endometrial adenoacanthoma and endometrial adenocarcinoma with malignant squamous cell differentiation[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 361-363.
[4] Q. Huang, Y. He, X. Cao, C. Yi. PTEN and CD146 expression in endometrioid adenocarcinoma[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 439-443.
[5] M. Szarszewska, J. Markowska, A. Czekała, P. Kurzawa. Coexistence of endocervical cancer and Brenner tumor of the ovary. Diagnostic difficulties[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 299-302.
[6] Mingming Sun, Tong Gao, Yuqing Zhao, Weiguo Hu, Wei Jiang. Primary fallopian tube carcinoma clinically manifested as vaginal adenocarcinoma in a post-hysterectomy patient: a case report and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 312-316.
[7] A. Temtanakitpaisan, K.-G. Huang, T. Temtanakitpaisan. Metachronous contralateral ovarian cancer after interval successful pregnancy[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1091-1092.
[8] H. Oikiri, M. Futagami, J. Watanabe, Y. Yokoyama. Adenocarcinoma of the cervix: its prognosis and difficult pathological diagnosis[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 728-733.
[9] S. Rahatli, H. Akilli, N. Haberal, O. Altundag, A. Haberal, A. Ayhan. Surgical management and outcomes of metastatic tumors to the ovaries[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 820-824.
[10] Yoshiya Miyahara, Hitomi Imafuku, Yuka Murata, Yasuhiko Ebina, Hideto Yamada. A retrospective analysis of giant ovarian tumors weighing more than 5,000 grams[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 563-566.
[11] J.J. Noh, H. Jung, C.H. Choi. Mesonephric adenocarcinoma treated with paclitaxel-carboplatin adjuvant chemotherapy: a case report[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 679-683.
[12] Q. Guo, Y. Huang, J. Xu, W. Wang, J. Gao, Y. Su, Y. Gu, X. Yin. Long non-coding RNA BANCR contributes to cervical adenocarcinoma migration by affecting epithelial-mesenchymal transition[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 408-412.
[13] Ha Kyun Chang, Yuki Gen, Seung Geun Yeo, Ji-Han Jung, Dong Choon Park. Primary adenocarcinoma with choriocarcinomatous differentiation of the sigmoid colon misdiagnosed choriocarcinoma of the uterus: case report and review of the literature[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 468-470.
[14] D. Wang, K.V. Adams, J.M. Lage, J.T. Lam. Uterine intravascular large B-cell lymphoma presenting as abnormal uterine bleeding[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 490-493.
[15] A. Di Cello, F. Visconti, P. Quaresima, G. Bitonti, F. Zullo. Vaginal clear cell adenocarcinoma in a young woman with a Müllerian duct anomaly and no history of in utero diethylstilbestrol exposure: a fertility-sparing approach[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 334-336.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[3] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[4] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[5] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[6] Z. Protrka, P. Arsenijevic, N. Jovic, S. Zivanovic, J. Djuric, A. Dimitrijevic. A case of uterine torsion in term pregnancy associated with placental abruption and intrauterine fetal demise[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 287 -289 .
[7] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[8] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[9] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .
[10] M.F. Benoit, K.A. O'Hanlan, M.S. Sten, C.L. Kosnik, D.M. Struck, M.S. O'Holleran, J. Cuff, D.M. Halliday, E.A. Kent. Incidental appendectomy at the time of gynecologic surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 386 -389 .